{
    "clinical_study": {
        "@rank": "143103", 
        "arm_group": [
            {
                "arm_group_label": "Arm A (standard of care treatment)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive standard of care treatment based on the discretion of the treating physician."
            }, 
            {
                "arm_group_label": "Arm B (genetic sequencing and targeted therapy)", 
                "arm_group_type": "Experimental", 
                "description": "Patients undergo collection of tissue and blood samples for analysis via sequencing. Upon disease progression following front-line treatment, patients receive specific targeted therapy based on the mutational status obtained during sequencing."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized clinical trial studies how well genetic sequencing-informed targeted therapy\n      works in treating patients with stage IIIB-IV non-small cell lung cancer. Targeted therapy\n      is a type of treatment that uses drugs or other substances to identify and attack specific\n      types of tumor cells that may have less harm to normal cells. Genetic sequencing may help\n      identify these specific types of tumor cells in patients with non-small cell lung cancer."
        }, 
        "brief_title": "Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer", 
        "condition": [
            "Malignant Pericardial Effusion", 
            "Malignant Pleural Effusion", 
            "Recurrent Non-small Cell Lung Cancer", 
            "Stage IIIB Non-small Cell Lung Cancer", 
            "Stage IV Non-small Cell Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Pericardial Effusion", 
                "Pleural Effusion", 
                "Pleural Effusion, Malignant"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. The three month progression free survival (PFS) of patients treated with targeted agents\n      in the second line setting based on the tumor molecular signature as defined by CancerCode\n      will be 40% vs 20% with standard cytotoxic chemotherapy.\n\n      SECONDARY OBJECTIVES:\n\n      I. Response rate (RR). II. Overall survival (OS). III. Proportion of Arm-B patients whose\n      second line therapy is changed as a result of physician access to CancerCode-50 results.\n\n      IV. Concordance of variants identified when sequencing is performed on samples from the same\n      patient collected at baseline and follow-up time points.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM A: Patients receive standard of care therapy based on the discretion of the treating\n      physician.\n\n      ARM B: Patients undergo collection of tissue and blood samples for analysis via sequencing.\n      Upon disease progression following front-line treatment, patients receive specific targeted\n      therapy based on the mutational status obtained during sequencing.\n\n      After completion of study treatment, patients are followed up every 3 months for 2 years,\n      every 6 months for 1 year, and then annually thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with cytologically or histologically confirmed non-small cell lung cancer\n             (NSCLC) - locally advanced, stage IIIB OR stage IV or stage IVM1A (malignant pleural\n             or pericardial effusion or pleural implants) OR recurrence after primary surgery or\n             radiotherapy (refer to 2010 American Joint Committee on Cancer [AJCC] staging, 7th\n             edition [Ed])\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\n          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)-1.1\n             criteria; previous irradiated tumor is acceptable if there is at least a 20% increase\n             in the size of the previously irradiated lesion\n\n          -  Patients must be suitable candidates for treatment with standard regimens; this\n             includes having adequate hematologic parameters, liver function and renal function\n             based on labs that are deemed acceptable for treatment by the investigators\n\n          -  Previous radiation allowed provided that 2 weeks has passed since radiation and/or\n             the patient has recovered from the side effects\n\n          -  Availability of archival diagnostic tissue (paraffin tissue block, cytospin block\n             from a fine needle aspirate, or unstained slides from resected tumor, core biopsy, or\n             fine needle aspirate) is required\n\n          -  Able and willing to sign an informed consent and Health Insurance Portability and\n             Accountability Act (HIPAA) authorization\n\n          -  Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP\n             must agree to use effective methods of contraception during active treatment and for\n             the duration of the study\n\n        Exclusion Criteria:\n\n          -  Prior treatment with any investigational or targeted therapies\n\n          -  Patients with known activating mutations in the epidermal growth factor receptor\n             (EGFR) gene or anaplastic lymphoma receptor tyrosine kinase (ALK) or c-ros oncogene\n             1, receptor tyrosine kinase (ROS-1) (this test [ROS-1] will be done only on select\n             patients and at the discretion of treating physicians) translocation positive; the\n             mutational status of all patients will be determined prior to study entry\n\n          -  Prior malignancy within the past 3 years other than complete resection of basal or\n             squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate\n             cancer after curative therapy\n\n          -  Prior systemic therapy within 14 days of initiating protocol treatment\n\n          -  Symptomatic brain metastasis or asymptomatic brain metastasis that are 1 cm or\n             greater in size; patients with asymptomatic sub-centimeter brain metastasis are\n             eligible\n\n          -  Uncontrolled or unstable medical or psychiatric co-morbidities which would clearly\n             limits patients participation\n\n          -  Current, recent (within 2 weeks of enrollment of this study), or planned\n             participation in an experimental drug study\n\n          -  Unstable angina\n\n          -  Pregnant (positive serum pregnancy test) or breast feeding\n\n          -  History of any disease that could lead to impaired absorption of drugs\n\n          -  Inability to comply with study and/or follow-up procedures\n\n          -  Prior allogeneic bone marrow or organ"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132884", 
            "org_study_id": "CGI-068", 
            "secondary_id": [
                "NCI-2014-00717", 
                "CGI-068", 
                "P30CA006927"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm B (genetic sequencing and targeted therapy)", 
                "description": "Undergo collection of tissue and blood samples", 
                "intervention_name": "cytology specimen collection procedure", 
                "intervention_type": "Other", 
                "other_name": "cytologic sampling"
            }, 
            {
                "arm_group_label": "Arm A (standard of care treatment)", 
                "description": "Receive standard of care treatment", 
                "intervention_name": "therapeutic procedure", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "Therapeutic Interventions", 
                    "Therapeutic Method", 
                    "Therapeutic Technique", 
                    "Therapy", 
                    "TX"
                ]
            }, 
            {
                "arm_group_label": "Arm B (genetic sequencing and targeted therapy)", 
                "description": "Receive specific targeted therapy", 
                "intervention_name": "targeted therapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm A (standard of care treatment)", 
                    "Arm B (genetic sequencing and targeted therapy)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "email": "hossein.borghaei@fccc.edu", 
                "last_name": "Hossein Borghaei", 
                "phone": "215-214-4297"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19111"
                }, 
                "name": "Fox Chase Cancer Center"
            }, 
            "investigator": {
                "last_name": "Hossein Borghaei", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "CancerCodeTM Informed, Molecularly Targeted Therapies in Non-small Cell Lung Cancer", 
        "other_outcome": [
            {
                "description": "The concordance of variants identified when sequencing will be performed on samples from the same patient collected at baseline and follow-up time points will also be measured.", 
                "measure": "Concordance of variants (Arm B)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "The incidence of non-protocol testing of those patients in Arm A who undergo molecular testing (by any method) at the discretion of the treating physician will be estimated.", 
                "measure": "Incidence of non-protocol testing (Arm A)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "The response rate of those patients in Arm A who undergo molecular testing (by any method) at the discretion of the treating physician will be estimated.", 
                "measure": "Response rate defined by RECIST 1.1 (Arm A)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "The progression free survival of those patients in Arm A who undergo molecular testing (by any method) at the discretion of the treating physician will be estimated.", 
                "measure": "Progression free survival (Arm A)", 
                "safety_issue": "No", 
                "time_frame": "Time from start of second line treatment to time of progression or death, whichever occurs first, assessed up to 2 year"
            }
        ], 
        "overall_official": {
            "affiliation": "Fox Chase Cancer Center", 
            "last_name": "Hossein Borghaei", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A chi-square test (one-sided; alpha = .1) will be used to assess the efficacy of treating patients with targeted agents based in the Cancer-Code-50 in the second line setting. For each patient \"success\" will be defined as being progression free for at least 3 months following initiation of second line therapy. Progression free survival times will be characterized separately by arm using the method of Kaplan and Meier.", 
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "Time from start of second line treatment to time of progression or death, whichever occurs first, assessed at 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132884"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The response rate (with 95% two-sided confidence intervals) will be computed separately by arm. One-sided chi-square or Fisher's exact tests (alpha = .1) will be used to evaluate differences in response rates between arms.", 
                "measure": "Response rate defined by RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "To assess the effect of sequencing on clinical practice and decision making the proportion of Arm B patients whose second line therapy is changed as a result of physician access to CancerCode-50 results will be computed. This comparison will be based on information provided by the treating physician before being exposed to the sequencing results, and information obtained from a from post-treatment chart review.", 
                "measure": "Proportion of Arm B patients whose second line therapy is changed as a result of physician access to CancerCode-50 results", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "Fox Chase Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fox Chase Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}